Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study
- PMID: 17355890
- PMCID: PMC1995655
- DOI: 10.1016/j.ygyno.2007.01.042
Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study
Abstract
Purpose: This report describes the strength and significance of the association between antecedent and mediating variables across four categories of quality of life (QOL) outcomes in 132 disease free women with ovarian germ cell survivors.
Methods: Survivors (n=132) participated in a mailed questionnaire and computer-assisted telephone survey. Participants in four prospective GOG protocols were contacted their treating physician for verbal consent to be approached by investigators at the Indiana University Cancer Center about a quality of life study. Similar patients treated at the MD Anderson Cancer Center were also included. If women verbally consented after being contacted by investigators at Indiana University, an informed consent and questionnaire packet was sent via mail. After return of the written informed consent and background questionnaire, a trained research assistant scheduled a computer-assisted interview to complete data collection.
Results: Median follow-up from diagnosis was 10.2 years. Mediating variables of self-efficacy or social support played a significant role (p=0.05 to p=0.001) in all four QOL categories: physical functioning, psychological functioning, sexual functioning, and spiritual functioning. Being a younger age at diagnosis and married were positively related to sexual functioning (p=0.05). Menstrual and gynecological symptoms were inversely related.
Implications: Results indicate that clinicians may want to be especially sensitive to identifying a survivor's social support and confidence (self efficacy) in handling issues evolving from treatment since these skills may be related to overall quality of life outcomes.
Similar articles
-
Quality of life after among ovarian germ cell cancer survivors: a narrative analysis.Oncol Nurs Forum. 2003 May-Jun;30(3):380. doi: 10.1188/03.ONF.E48-E54. Oncol Nurs Forum. 2003. PMID: 12719752
-
Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.J Clin Oncol. 2007 Jul 1;25(19):2792-7. doi: 10.1200/JCO.2006.08.4590. J Clin Oncol. 2007. PMID: 17602084
-
Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study.J Psychosoc Oncol. 2008;26(3):19-42. doi: 10.1080/07347330802115715. J Psychosoc Oncol. 2008. PMID: 19042263 Clinical Trial.
-
Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors.Psychooncology. 2007 Aug;16(8):691-706. doi: 10.1002/pon.1208. Psychooncology. 2007. PMID: 17628036 Review.
-
Survivorship issues in ovarian cancer: a review.Oncol Nurs Forum. 2006 May 3;33(3):553-62. doi: 10.1188/06.ONF.553-562. Oncol Nurs Forum. 2006. PMID: 16676012 Review.
Cited by
-
Women with Ovarian Cancer: Examining the Role of Social Support and Rumination in Posttraumatic Growth, Psychological Distress, and Psychological Well-being.J Clin Psychol Med Settings. 2017 Mar;24(1):47-58. doi: 10.1007/s10880-016-9482-7. J Clin Psychol Med Settings. 2017. PMID: 28124180
-
The course and predictors of perceived unsupportive responses by family and friends among women newly diagnosed with gynecological cancers.Transl Behav Med. 2019 Jul 16;9(4):682-692. doi: 10.1093/tbm/iby087. Transl Behav Med. 2019. PMID: 30189025 Free PMC article. Clinical Trial.
-
Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.Ann Transl Med. 2020 Dec;8(24):1713. doi: 10.21037/atm.2020.04.15. Ann Transl Med. 2020. PMID: 33490225 Free PMC article. Review.
-
Ovarian cancer survivors' quality of life: a systematic review.J Cancer Surviv. 2016 Oct;10(5):789-801. doi: 10.1007/s11764-016-0525-8. Epub 2016 Feb 17. J Cancer Surviv. 2016. PMID: 26884372
-
Fertility preservation in women with cervical, endometrial or ovarian cancers.Gynecol Oncol Res Pract. 2016 Jul 27;3:8. doi: 10.1186/s40661-016-0029-2. eCollection 2016. Gynecol Oncol Res Pract. 2016. PMID: 27468354 Free PMC article. Review.
References
-
- Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG, Wharton JT. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. Journal of Clinical Oncology. 1990;8(4):715–20. - PubMed
-
- Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. Journal of Clinical Oncology. 1994;12(4):701–706. - PubMed
-
- Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced recurrent ovarian germ-cell tumors. Annals of Internal Medicine. 1989;111:22–27. - PubMed
-
- Matei DE, Russell AH, Horowitz CJ, Gershenson DM, Silva EG. Ovarian germ-cell tumors. In: Hoskins WE, et al., editors. Principles and practice of gynecologic oncology. Lippincott Williams & Wilkins; Philadelphia, PA: 2005.
-
- Hale GA, Marina NM, Jones-Wallace D, Greenwald CA, Jenkins JJ, Rao BN, Luo X, Hudson MM. Late effects of treatment for germ cell tumors during childhood and adolescence. Journal of Pediatric Hematology/Oncology. 1999;21(2):115–22. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical